Comprehensive Overview of Mantle Cell Lymphoma: Diagnosis, Treatment, and Emerging Therapies

Speakers: Olivier Hermine

Olivier Hermine
Olivier Hermine MD, PhD is a professor of hematology at the University of Paris Cité, head of the clinical department of hematology and founder and coordinator of the national reference center on mastocytosis at the Hospital Necker Enfants-Malades. He is also head of a research group on physiopathology and treatment of hematological disorders at the Imagine Institute and founder and coordinator of the laboratories of excellence on red cells in France. He teaches hematology both basic and clinical at different levels from undergraduate to MD and PhD at the Paris-cité University. He is a board member of Imagine Institute in charge of clinical and translational research committee and co-founder and scientific director of the Ecole Polytechnique-HEC Bioentreprenor programm.

He is current member of the American Society of Hematology and active member of the Red cell committee. He is a board member of EBMT Lymphoma working group and chairman of the Mantle cell sub-committee, European Mantle cell network, member of the scientific and administrative committee and coordinator of the Mantle cell group of the LYSA (French Lymphoma study group), and of the international retrovirology association (IRVA; HTLV-1 and related virus including T cell lymphoma) and co-founder and scientific director of the French CELAC group on Intestinal Lymphoma and active participant of the ECNM the European network of mastocytosis. He is elected member of the French national academy of science, French national academy of pharmacy, Belgium Royal academy of medicine, and of Academia Europa in the human and veterinarian medicine.

He is co-author of more than 995 peer review publications in International Scientific Journals. He is co-founder of two biotechnologies (Inatherys (monoclonal antibodies against Transferin receptor in hematological malignancies) and AB Science (kinase inhibitor). Overall his research tries to understand and study mechanisms underlying several haematological malignancies and benign hematological disorders in humans and animals, in order to improve care and develop targeted and immune therapies.